SCHEMBL24315947

SCHEMBL24315947

O=C1Nc2cccc3c(CC4CN(Cc5ccccc5)C4)ccc1c23

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.41
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
FUCA1 P04066 2/20 0.38
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 2/20 0.37
S1PR1 P21453 1/20 0.37
S1PR5 Q9H228 1/20 0.37
POLB P06746 1/20 0.37
KDR P35968 1/20 0.37
TSHR P16473 2/20 0.37
CASP1 P29466 2/20 0.37
CASP7 P55210 2/20 0.37
USP2 O75604 1/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TYMS P04818 1/20 0.36
EPHX2 P34913 1/20 0.36
ACHE P22303 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29611183 1.00 PARP1 (0.41) PARP1DRD2DRD4DRD3FUCA1
SCHEMBL24315945 0.78 POLB (0.45) PARP1KDM4EALDH1A1POLBKDR
SCHEMBL29774617 0.77 PARP1 (0.51) PARP1KDM4EALDH1A1ACHE
SCHEMBL24316270 0.76 PARP1 (0.44) PARP1DRD2DRD4DRD3KDM4E
SCHEMBL24315780 0.75 PARP1 (0.41) PARP1DRD2DRD4DRD3KDM4E
SCHEMBL29611207 0.73 OPRL1 (0.48) PARP1DRD2DRD4DRD3KDM4E
SCHEMBL24316271 0.73 OPRL1 (0.48) PARP1DRD2DRD4DRD3KDM4E
SCHEMBL29610675 0.73 PARP1 (0.41) PARP1KDM4EALDH1A1POLBTSHR
SCHEMBL24315946 0.73 PARP1 (0.41) PARP1KDM4EALDH1A1POLBTSHR
SCHEMBL24315954 0.73 CRBN (0.45) ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
CN-116783180-A Tricyclic ligands for degradation of IKZF2 or IKZF4 C4医药公司 2023-09-19 CN disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 PARP1 1566/4885DRD2 4565/4885DRD4 4322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.